

ESGCD Executive Committee Meeting
Friday 11th November 2011 @ 11.30am
Board Room, Health Protection Surveillance Centre, Dublin Ireland

Attending:

*Ed Kuijper (EK)
Jean O'Driscoll (JO'D)
Fidelma Fitzpatrick (FF)
*Mark Wilcox (MW)
*Richard Bax (RB)
*Petra Gastmeier (PG)
* Paola Mastrantonio

*By teleconference

Apologies:

Frederic Barbut
Emilio Bouza

Agenda Items:

1. Minutes of previous Business Meeting 9th May 2011 Milano, Italy (previously circulated).

Minutes of the last business meeting 9th May 2011 Milano Italy were approved, no changes were proposed.

2. Agenda Meeting Dublin

EK had circulated the agenda prior the meeting. FF agreed to chair today's meeting.

3. Point prevalence study ESGCD with Astellas (attached)

MW summarised and informed the committee on the background of the proposal from Astellas Pharma Europe Ltd. on the European, multi-centre, prospective bi-annual point prevalence study of the incidence of *Clostridium difficile* Infection in patients with nosocomial Diarrhoea (EUCLID). This document was previously circulated to all committee in advance of the meeting. The study is based on the national point prevalence study carried out in Spain by the Spanish C.difficile Study Group.

The proposal is for ESGCD to undertake the responsibility for implementation and management of the study on behalf of and in close collaboration with APEL who will provide funding and additional support. The length of the study is 2 years and collection will take place bi-annually. Initially the study will take place in 6 countries that have existing national surveillance programs and then rolled to 20 countries.

The group discussed the proposal in great detail particularly the funding and management aspects. The overall consensus was to carry out the study however the ownership must be clearly stated and adequate funding provided.

Action point: EK & MW agreed to report back to Astellas Pharma Europe Ltd with a discussed proposal.

4. Performance of the SG according to (attached) ESCMID criteria

ESGCD performed very well in 2010/1, being the second best-performing group pipped only by EHSB (European Helicobacter Study Group). The Lancet paper had not been included in the evaluation.

5. Results ESGCD for ECCMID 2012, London

22nd European Congress of Clinical Microbiology and Infectious Diseases, which will be held in London from 31st March to 3rd April 2012. The Programme Committee has created a comprehensive series of lectures, educational workshops and meet-the expert sessions, covering the entire field of infection-related diseases. ECCMID have approved two sessions for the ESGCD results in London 2012. The following were agreed:

- 1) the epidemiology and clinical relevance of *C. difficile* in specific populations e.g. children, patients with IBD, patients in nursing home and
- 2) *C. difficile* infections and recurrences, different types, different treatments

Action point: Committee members were reminded by EK to submit abstracts of their work in relation to *C. difficile* if possible.

6. Progress ECDC project (Supporting capacity building for CDI at European level)

EK updated the committee on the kick-off meeting of the ECDC/ESCMID collaboration on "Supporting capacity building for surveillance of *Clostridium difficile* infections at European level" that took place in Berlin June 2011. All 4 work packages are progressing well to date. Two questionnaires have been developed; the response to the first on what individual countries are doing will be presented at next year's ECCMID. The second, regarding incidence of CDI, has been circulated. The next step is a workshop on diagnostics that will take place in Leeds or Leiden on the 14th and 15th March 2012. Attendees will carry out a practical workshop for a two day period. All funding will be covering by ECDC. One delegate per country should attend; 25 countries are taking part.

7. Financial Update

Frédéric Barbut sent his apologies. SD agreed to request a financial update from FB for inclusion to the minutes.

8. Study *C.difficile* among Health Care Workers, proposal Markus Hell (attached)

Markus Hell contacted EK to distribute his proposal on a study on *C. difficile* among Health Care Workers (this was previously circulated to all committee members) After an extensive debate among the group the overall consensus is that this study is not feasible due to a number of ethical reasons.

9. Any other Business

The 4th International *C. difficile* Symposium will be held at Bled, Slovenia from the 20th to the 22nd of September 2012. Anne Collignon and Paula Mastrantonio are on the Organising Committee.